Despite high vaccination coverage worldwide, pertussis has re-emerged in many countries.
This randomized, controlled, observer-blind phase I study and extension study in Belgium …

ABSTRACT Background: An acellular Pertussis (aP) vaccine containing recombinant
genetically detoxified Pertussis Toxin (PTgen), Filamentous Hemagglutinin (FHA) and …

Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …

Background Protection induced by acellular pertussis (aP) vaccines is partial and short-
lived, especially in teenagers, calling for novel immunization strategies. Methods We …

Combination vaccines containing a monocomponent acellular pertussis (aP) vaccine,
manufactured at Statens Serum Institut (SSI), Denmark, have successfully controlled …

Pertussis is increasingly being recognized as an important cause of cough illness in
adolescents and adults. To evaluate the safety and immunogenicity of an adult formulation …

Universal pertussis vaccination continues to prevent a previously common and serious
disease of childhood. Despite widespread gains in disease control, pertussis has not been …

BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …

Background Recombinant pertussis vaccines inducing long-lasting immune responses
could help to control the rise in pertussis. We here report on persisting antibody responses 2 …

A single blinded randomized controlled trial to compare the reactogenicity and
immunogenicity of adult formulated dTpa and monovalent pa vaccines with a licensed Td …